NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, Price Target & More

Get Started

$17.01 -0.24 (-1.39 %)

(As of 05/23/2018 04:00 PM ET)

Previous Close$17.24

Today's Range$16.98 - $17.75

52-Week Range$14.51 - $41.20

Volume98,760 shs

Average Volume3.76 million shs

Market Capitalization$2.21 billion

P/E Ratio-7.27

Dividend YieldN/A

Beta3.37

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ACAD

CUSIPN/A

Webwww.acadia-pharm.com

Phone858-558-2871

Debt

Debt-to-Equity RatioN/A

Current Ratio7.38

Quick Ratio7.26

Price-To-Earnings

Trailing P/E Ratio-7.27

Forward P/E Ratio-9.95

P/E GrowthN/A

Sales & Book Value

Annual Sales$124.90 million

Price / Sales17.00

Cash FlowN/A

Price / CashN/A

Book Value$2.44 per share

Price / Book6.97

Profitability

EPS (Most Recent Fiscal Year)($2.36)

Net Income$-289,400,000.00

Net Margins-161.44%

Return on Equity-71.47%

Return on Assets-63.74%

Miscellaneous

Employees425

Outstanding Shares124,830,000

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings data on Friday, May, 4th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.12. The biopharmaceutical company had revenue of $48.90 million for the quarter, compared to the consensus estimate of $47.06 million. ACADIA Pharmaceuticals had a negative return on equity of 71.47% and a negative net margin of 161.44%. The company's quarterly revenue was up 219.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.72) EPS. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for ACADIA Pharmaceuticals.

What price target have analysts set for ACAD?

11 brokers have issued 12-month target prices for ACADIA Pharmaceuticals' stock. Their forecasts range from $45.00 to $61.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $50.40 in the next twelve months. View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (5/9/2018)
2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 13,203,966 shares, an increase of 16.7% from the March 30th total of 11,319,177 shares. Based on an average trading volume of 5,224,064 shares, the days-to-cover ratio is presently 2.5 days. Currently, 10.7% of the company's shares are short sold.

Who are some of ACADIA Pharmaceuticals' key competitors?

Some companies that are related to ACADIA Pharmaceuticals include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:

Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
Mr. Todd S. Young, Exec. VP, CFO & Principal Accounting Officer (Age 46)
Mr. Glenn F. Baity, Exec. VP, Gen. Counsel and Sec. (Age 48)
Dr. Srdjan R. Stankovic M.D., M.S.P.H., Head of R&D and Exec. VP (Age 61)
Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

Media headlines about ACAD stock have trended positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.40 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.09 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.33%), OppenheimerFunds Inc. (3.48%), Franklin Resources Inc. (1.74%), JPMorgan Chase & Co. (1.54%), Palo Alto Investors LP (1.32%) and Millennium Management LLC (0.53%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Edmund Harrigan, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., OppenheimerFunds Inc., Stanley Laman Group Ltd., Eventide Asset Management LLC, Prudential Financial Inc., BlackRock Inc., SG Americas Securities LLC and JPMorgan Chase & Co.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Frontier Capital Management Co. LLC, The Manufacturers Life Insurance Company , First Washington CORP, Handelsbanken Fonder AB, Handelsbanken Fonder AB and Massachusetts Financial Services Co. MA. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Daniel B Soland and Edmund Harrigan. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $17.01.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $2.21 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]

MarketBeat Community Rating for ACADIA Pharmaceuticals (ACAD)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		526 (Vote Outperform)
Underperform Votes:		239 (Vote Underperform)
Total Votes:		765

MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

11 Wall Street analysts have issued ratings and price targets for ACADIA Pharmaceuticals in the last 12 months. Their average twelve-month price target is $50.40, suggesting that the stock has a possible upside of 196.30%. The high price target for ACAD is $61.00 and the low price target for ACAD is $45.00. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.82	2.83	2.83	2.83
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$50.40	$51.2727	$51.2727	$49.4167
Price Target Upside:	196.30% upside	189.02% upside	73.04% upside	66.78% upside

ACADIA Pharmaceuticals (NASDAQ:ACAD) Consensus Price Target History

Price Target History for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/16/2018	HC Wainwright	Reiterated Rating	Buy		Medium
4/10/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$50.00	High
11/7/2017	Cowen	Reiterated Rating	Buy	$46.00	N/A
10/12/2017	Jefferies Group	Reiterated Rating	Buy	$47.00	N/A
10/9/2017	Leerink Swann	Reiterated Rating	Market Perform		N/A
10/6/2017	Goldman Sachs Group	Reiterated Rating	Neutral	$45.00	N/A
10/5/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$54.00 ➝ $61.00	N/A
10/5/2017	Bank of America	Boost Price Target	Buy ➝ Positive	$40.00 ➝ $46.00	N/A
10/5/2017	JMP Securities	Boost Price Target	Outperform	$47.00 ➝ $50.00	N/A
10/2/2017	Ladenburg Thalmann	Reiterated Rating	Buy	$48.00 ➝ $50.00	Low
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$49.00	Low
5/22/2017	Rodman & Renshaw	Reiterated Rating	Buy	$60.00	Low
10/19/2016	Roth Capital	Reiterated Rating	Neutral	$25.00	N/A
8/5/2016	Aegis	Downgrade	Buy ➝ Hold	$54.00 ➝ $41.00	N/A

(Data available from 5/23/2016 forward)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings History and Estimates Chart

Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.91)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.55)	($0.55)	($0.55)
Q2 2018	1	($0.50)	($0.50)	($0.50)
Q3 2018	1	($0.45)	($0.45)	($0.45)
Q4 2018	1	($0.41)	($0.41)	($0.41)

ACADIA Pharmaceuticals (NASDAQ ACAD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		($0.46)					N/A
5/4/2018	3/31/2018	($0.56)	($0.44)	$47.06 million	$48.90 million	View	N/A
2/27/2018	Q4 2017	($0.58)	($0.55)	$45.30 million	$43.56 million	View	Listen
11/7/2017	Q3 2017	($0.63)	($0.53)	$32.03 million	$35.58 million	View	N/A
8/8/2017	Q2 2017	($0.72)	($0.55)	$20.02 million	$30.50 million	View	Listen
5/9/2017	Q1 2017	($0.7310)	($0.72)	$15.17 million	$15.30 million	View	Listen
2/28/2017	Q416	($0.65)	($0.65)	$9.05 million	$12.00 million	View	Listen
11/7/2016	Q316	($0.56)	($0.61)	$2.90 million	$5.30 million	View	Listen
8/4/2016	Q216	($0.49)	($0.63)	$0.71 million	$0.97 million	View	Listen
5/5/2016	Q116	($0.42)	($0.45)	$0.22 million		View	Listen
2/29/2016	Q415	($0.38)	($0.45)		$0.02 million	View	Listen
11/5/2015	Q315	($0.40)	($0.39)	$0.05 million	$0.04 million	View	Listen
8/6/2015	Q215	($0.33)	($0.39)	$0.06 million		View	Listen
5/7/2015	Q115	($0.25)	($0.40)	$0.09 million		View	Listen
2/26/2015	Q414	($0.26)	($0.28)	$0.08 million	$0.05 million	View	Listen
11/10/2014	Q3	($0.12)	($0.25)		$0.02 million	View	Listen
8/5/2014	Q2	($0.17)	($0.22)	$0.10 million	$0.03 million	View	Listen
5/6/2014	Q1	($0.13)	($0.19)	$0.50 million	$0.03 million	View	Listen
2/27/2014	Q4	($0.14)	($0.13)	$0.30 million	$0.04 million	View	Listen
11/6/2013	Q3 2013	($0.12)	($0.12)	$0.25 million	$0.24 million	View	N/A
8/6/2013	Q2 2013	($0.09)	($0.11)	$0.45 million	$451.00 million	View	Listen
5/7/2013	Q1 2013	($0.08)	($0.08)	$0.45 million	$0.4170 million	View	Listen
3/12/2013	Q4 2012	($0.08)	($0.11)			View	N/A
11/5/2012	Q312	($0.09)	($0.04)	$1.90 million	$3.50 million	View	N/A
8/8/2012	Q2 2012	($0.12)	($0.10)			View	N/A
5/8/2012	Q1 2012	($0.11)	($0.12)			View	N/A
3/6/2012	Q4 2011	($0.10)	($0.10)			View	N/A
11/9/2011	Q3 2011	($0.10)	($0.10)			View	N/A
8/10/2011	Q2 2011	($0.15)	($0.10)			View	N/A
5/10/2011	Q1 2011	($0.11)	($0.12)			View	N/A
3/10/2011	Q4 2010	$0.69	$0.74			View	N/A
11/9/2010	Q3 2010	($0.17)	($0.11)			View	N/A
8/9/2010	Q2 2010	($0.16)	($0.11)			View	N/A
5/10/2010	Q1 2010	($0.17)	($0.14)			View	N/A
3/9/2010	Q4 2009	($0.19)	($0.23)			View	N/A
11/9/2009	Q3 2009	($0.27)	($0.23)			View	N/A
8/5/2009	Q2 2009	($0.34)	($0.34)			View	N/A
5/11/2009	Q1 2009	($0.36)	($0.40)			View	N/A
3/9/2009	Q4 2008	($0.38)	($0.38)			View	N/A
11/5/2008	Q3 2008	($0.43)	($0.36)			View	N/A
8/5/2008	Q2 2008	($0.46)	($0.49)			View	N/A
5/5/2008	Q1 2008	($0.46)	($0.44)			View	N/A
3/5/2008	Q4 2007	($0.46)	($0.46)			View	N/A

(Earnings results data provided by Zacks Investment Research)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.19%

Insider Trading History for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2018	Daniel B Soland	Director	Buy	7,000	$23.91	$167,370.00	2,000
1/29/2018	Glenn Baity	EVP	Sell	36,558	$32.39	$1,184,113.62	83,734
1/2/2018	Glenn Baity	EVP	Sell	74,321	$30.14	$2,240,034.94
1/2/2018	Laura Brege	Director	Sell	25,000	$30.06	$751,500.00	15,000
10/5/2017	Glenn Baity	EVP	Sell	37,500	$40.91	$1,534,125.00
8/30/2017	Glenn Baity	EVP	Sell	26,507	$34.87	$924,299.09	94,163
8/9/2017	Glenn Baity	EVP	Sell	14,322	$34.88	$499,551.36	78,578
7/20/2017	Glenn Baity	EVP	Sell	38,097	$30.00	$1,142,910.00	109,253
6/22/2017	Glenn Baity	EVP	Sell	1,903	$30.00	$57,090.00	83,059
2/16/2017	Terrence O. Moore	EVP	Sell	157,540	$39.77	$6,265,365.80
12/27/2016	Glenn Baity	EVP	Sell	9,800	$30.46	$298,508.00	81,363
12/20/2016	Glenn Baity	EVP	Sell	10,000	$30.00	$300,000.00
8/16/2016	Edmund Harrigan	Director	Buy	1,000	$32.97	$32,970.00	1,000
8/10/2016	Bros. Advisors Lp Baker	Director	Buy	1,303,030	$33.00	$42,999,990.00
7/12/2016	Glenn Baity	EVP	Sell	16,000	$35.00	$560,000.00	66,978
7/11/2016	Glenn Baity	EVP	Sell	4,057	$35.00	$141,995.00	66,978
4/18/2016	Leslie L Iversen	Director	Sell	33,697	$33.53	$1,129,860.41	69,824
4/1/2016	Bros. Advisors Lp Baker	Director	Buy	1,449,090	$27.08	$39,241,357.20
1/7/2016	L.P. 14159	Director	Buy	2,586,206	$29.00	$74,999,974.00
11/11/2015	Leslie L. Iversen	Director	Sell	30,000	$36.01	$1,080,300.00	36,127
1/15/2015	Michael T Borer	Director	Sell	27,973	$33.02	$923,668.46
1/14/2015	Uli Hacksell	CEO	Sell	30,000	$33.98	$1,019,400.00
12/15/2014	Mary Ann Gray	Director	Sell	12,250	$31.74	$388,815.00
12/15/2014	Uli Hacksell	CEO	Sell	30,000	$31.00	$930,000.00
11/26/2014	Michael T Borer	Director	Sell	15,000	$30.05	$450,750.00
11/26/2014	Roger Mills	CMO	Sell	25,000	$30.09	$752,250.00
11/24/2014	Uli Hacksell	CEO	Sell	30,000	$29.28	$878,400.00
11/21/2014	William Mcdowall Wells	Director	Sell	5,810	$29.00	$168,490.00
10/8/2014	Uli Hacksell	CEO	Sell	30,000	$24.15	$724,500.00
9/15/2014	Laura Brege	Director	Sell	10,000	$28.07	$280,700.00
9/12/2014	William Mcdowall Wells	Director	Sell	9,190	$29.15	$267,888.50
9/10/2014	Uli Hacksell	CEO	Sell	30,000	$27.36	$820,800.00
8/15/2014	Uli Hacksell	CEO	Sell	15,000	$22.89	$343,350.00
7/14/2014	Uli Hacksell	CEO	Sell	20,000	$22.22	$444,400.00
6/16/2014	Uli Hacksell	CEO	Sell	20,000	$23.10	$462,000.00
6/9/2014	William Mcdowall Wells	Director	Sell	15,000	$23.03	$345,450.00
5/1/2014	Torsten Rasmussen	Director	Sell	32,857	$20.03	$658,125.71
4/15/2014	Uli Hacksell	CEO	Sell	25,000	$17.75	$443,750.00
4/4/2014	Thomas Aasen	CFO	Sell	15,000	$22.48	$337,200.00	23,848
4/4/2014	Torsten Rasmussen	Director	Sell	30,000	$21.98	$659,400.00
3/5/2014	Bros. Advisors Lp Baker	Director	Buy	526,316	$28.50	$15,000,006.00
2/26/2014	Glenn Baity	VP	Sell	42,000	$30.28	$1,271,760.00	47,788
11/1/2013	Torsten Rasmussen	Director	Sell	37,692	$23.00	$866,916.00
11/1/2013	Uli Hacksell	CEO	Sell	15,000	$23.24	$348,600.00
10/10/2013	Laura Brege	Director	Sell	10,000	$21.63	$216,300.00
10/1/2013	Thomas H Aasen	CFO	Sell	30,000	$27.87	$836,100.00
9/20/2013	Roger Mills	CMO	Sell	35,965	$25.01	$899,484.65	15,775
9/12/2013	Lester Ph Kaplan	Director	Sell	66,356	$22.90	$1,519,552.40	8,500
9/10/2013	Laura Brege	Director	Sell	46,153	$22.80	$1,052,288.40
9/3/2013	Torsten Rasmussen	Director	Sell	40,000	$20.28	$811,200.00
8/26/2013	Mary Ann Gray	Director	Sell	15,000	$20.68	$310,200.00
8/13/2013	Thomas Aasen	CFO	Sell	60,000	$20.15	$1,209,000.00	31,585
8/13/2013	Uli Hacksell	CEO	Sell	52,771	$20.14	$1,062,807.94
6/5/2013	Felix Baker	Director	Buy	2,340,314	$14.34	$33,560,102.76
5/15/2013	Felix Baker	Director	Buy	1,993,000	$12.50	$24,912,500.00
4/12/2013	Glenn Baity	VP	Sell	60,000	$12.42	$745,200.00
4/11/2013	Thomas H Aasen	CFO	Sell	40,000	$11.06	$442,400.00

(Data available from 1/1/2013 forward)

ACADIA Pharmaceuticals (NASDAQ ACAD) News Headlines

Source:

Date	Headline
	Is Acadia Pharmaceuticals (ACAD) a Buy? finance.yahoo.com - May 23 at 8:41 AM
	$59.32 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (ACAD) This Quarter www.americanbankingnews.com - May 23 at 2:10 AM
	Brokerages Anticipate ACADIA Pharmaceuticals Inc. (ACAD) Will Post Earnings of -$0.46 Per Share www.americanbankingnews.com - May 21 at 7:10 PM
	Acadia Pharmaceuticals (ACAD) Rating Reiterated by HC Wainwright www.americanbankingnews.com - May 19 at 10:56 AM
	Better Buy: Acadia Pharmaceuticals vs. Biogen www.fool.com - May 18 at 2:40 PM
	Acadia Pharmaceuticals (ACAD) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - May 16 at 4:50 PM
	Edited Transcript of ACAD earnings conference call or presentation 4-May-18 12:30pm GMT finance.yahoo.com - May 15 at 5:24 PM
	Interesting ACAD Put And Call Options For June 29th www.nasdaq.com - May 10 at 5:21 PM
	Acadia Pharmaceuticals (ACAD) Cut to Hold at Zacks Investment Research www.americanbankingnews.com - May 9 at 5:09 PM
	ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018 finance.yahoo.com - May 8 at 5:07 PM
	Acadia: Damn The Torpedoes, Full Speed Ahead seekingalpha.com - May 8 at 8:47 AM
	Acadia Pharmaceuticals (ACAD) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - May 7 at 1:48 PM
	Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Portola Pharmaceuticals finance.yahoo.com - May 7 at 8:45 AM
	Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1 finance.yahoo.com - May 7 at 8:45 AM
	Acadia Pharmaceuticals (ACAD) Expected to Announce Quarterly Sales of $58.99 Million www.americanbankingnews.com - May 6 at 4:12 AM
	ACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 4 at 5:00 PM
	Why Acadia Pharmaceuticals Jumped 11% Higher Today finance.yahoo.com - May 4 at 5:00 PM
	Acadia Pharmaceuticals (ACAD) Announces Quarterly Earnings Results www.americanbankingnews.com - May 4 at 4:36 PM
	Acadia Pharmaceuticals (ACAD) Expected to Announce Earnings of -$0.56 Per Share www.americanbankingnews.com - May 4 at 11:30 AM
	Earnings Reaction History: ACADIA Pharmaceuticals Inc, 66.7% Follow-Through Indicator, 9.2% Sensitive www.nasdaq.com - May 4 at 8:46 AM
	Form 8-K ACADIA PHARMACEUTICALS For: May 04 www.streetinsider.com - May 4 at 8:46 AM
	Acadia Pharma Q1 Nuplazid sales $48.9M; shares up 5% premarket seekingalpha.com - May 4 at 8:46 AM
	ACADIA Posts Narrower than Expected Loss in Q1, Sales Beat www.zacks.com - May 4 at 8:46 AM
	BRIEF-Acadia Pharmaceuticals Q1 Loss Per Share $0.44 www.reuters.com - May 4 at 8:46 AM
	ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results finance.yahoo.com - May 4 at 8:46 AM
	Acadia: 1Q Earnings Snapshot finance.yahoo.com - May 4 at 8:46 AM
	ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations finance.yahoo.com - May 2 at 5:09 PM
	Acadia Pharmaceuticals (ACAD) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - May 1 at 6:06 PM
	ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018 finance.yahoo.com - May 1 at 4:54 PM
	Will ACADIA (ACAD) Disappoint Investors This Earnings Season? finance.yahoo.com - May 1 at 4:54 PM
	BRIEF-Acadia Pharmaceuticals Says CEO Stephen Davis's FY 2017 Total Compensation Was $15.2 Mln www.reuters.com - May 1 at 8:53 AM
	Acadia Pharmaceuticals (ACAD) to Release Quarterly Earnings on Monday www.americanbankingnews.com - April 30 at 7:10 AM
	Acadia stands behind risk/benefit profile of Nuplazid; shares up 4% premarket seekingalpha.com - April 27 at 9:08 AM
	RSI Alert: Acadia Pharmaceuticals (ACAD) Now Oversold www.nasdaq.com - April 26 at 8:41 AM
	Here’s What Just Happened With Acadia finance.yahoo.com - April 26 at 8:41 AM
	Today’s Research Reports on Stocks to Watch: Dare Bioscience and ACADIA finance.yahoo.com - April 26 at 8:41 AM
	Acadia Pharmaceuticals (ACAD) Short Interest Up 16.7% in April www.americanbankingnews.com - April 26 at 2:22 AM
	FDA says reviewing Acadia's Parkinson's medication, shares fall finance.yahoo.com - April 25 at 5:08 PM
	This Explains Why Acadia Pharmaceuticals Is Selling Off Today finance.yahoo.com - April 25 at 5:08 PM
	PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease www.businesswire.com - April 23 at 4:54 PM
	Zacks Investment Research Upgrades Acadia Pharmaceuticals (ACAD) to "Buy" www.americanbankingnews.com - April 19 at 11:33 AM
	Acadia Pharmaceuticals (ACAD) Upgraded to Hold by BidaskClub www.americanbankingnews.com - April 19 at 11:11 AM
	$46.52 Million in Sales Expected for Acadia Pharmaceuticals (ACAD) This Quarter www.americanbankingnews.com - April 19 at 4:23 AM
	Analysts Anticipate Acadia Pharmaceuticals (ACAD) Will Post Earnings of -$0.56 Per Share www.americanbankingnews.com - April 17 at 8:00 AM
	Acadia Pharmaceuticals (ACAD) Upgraded by BidaskClub to "Hold" www.americanbankingnews.com - April 16 at 7:35 PM
	Acadia Pharmaceuticals (ACAD) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - April 12 at 1:41 PM
	Acadia Pharmaceuticals' (ACAD) "Buy" Rating Reaffirmed at HC Wainwright www.americanbankingnews.com - April 11 at 11:23 PM
	Acadia Pharma up 6% on FDA OK on risk disclosures for Nuplazid seekingalpha.com - April 11 at 5:02 PM
	Acadia Pharmaceuticals' (ACAD) "Outperform" Rating Reiterated at Cowen www.americanbankingnews.com - April 11 at 4:31 PM
	Acadia Pharmaceuticals (ACAD) Raised to Sell at ValuEngine www.americanbankingnews.com - April 11 at 3:58 PM

ACADIA Pharmaceuticals (NASDAQ:ACAD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

ACADIA Pharmaceuticals (NASDAQ:ACAD) Income Statement, Balance Sheet and Cash Flow Statement

ACADIA Pharmaceuticals (NASDAQ ACAD) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff